European Study of HF0220 in Mild to Moderate Alzheimer's Disease Patients
Status:
Completed
Trial end date:
2008-08-01
Target enrollment:
Participant gender:
Summary
The purpose of this Phase II study is to evaluate the safety and tolerability of HF 0220 in
patients with Alzheimer's disease compared to placebo (inactive substance). The study will
also validate biochemical markers as appropriate clinical end-points and to assess the
suitability of chosen dose levels for future clinical studies.